Abstract
Presentation Description :
There is a long-standing interest to quantitativly measure retinal blood flow. Although the first paper quantifying retinal blood flow was published almost 40 years ago by Charles Riva it still has not been implemented in clinical praxis. This is partially related to the technical difficulties in obtaining reproducible results in patients with ocular disease. Recently there is increased interest in the topic because optical coherence tomography angiography (OCTA) has become commercially available and has been used by clinicians in a wide variety of ocular diseases. Whereas OCTA is capable of visualizing the retinal vasculature with unprecedented detail there is currently no algorithm available to quantify blood flow. Parameters such as vessel density and perfusion density have been linked to ocular and systemic disease, but provide no information on perfusion per se. The present talk gives an overview of what is required in terms of instrumentation and which studies are required to establish retinal blood flow as biomarker.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.